Mirum Pharmaceuticals (MIRM) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 15, 2026, at the company’s headquarters in Foster City, CA.

• Shareholders are invited to vote on key proposals, including director elections, auditor ratification, and executive compensation.

Voting matters and shareholder proposals

• Election of three Class I director nominees to serve until the 2029 annual meeting or until successors are qualified.

• Ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026.

• Advisory vote to approve named executive officer compensation as disclosed in the proxy statement.

• Proxyholders have discretionary authority to vote on other business that may arise at the meeting.

Board of directors and corporate governance

• Board recommends voting in favor of all director nominees and proposals.

• Nominees for Class I directors are Lon Cardon, Ph.D., FMedSci, William Fairey, and Timothy Walbert.